Mukka Proteins plans ₹47 Crore preferential issue via warrants
Mukka Proteins Limited is proposing to issue 2 Crore Convertible Warrants at ₹23.50 each, aggregating ₹47 Crore. The warrants are convertible into equity shares within 18 months. The company has applied for in-principle approval from stock exchanges and will seek shareholder approval via postal ballot. E-voting period is June 13 to July 12, 2026.
The preferential issue of ₹47 Crore can significantly impact the company's capital structure and future equity dilution. It is a material event requiring shareholder and regulatory approval.
The announcement is about a proposed preferential issue of warrants, which is a standard corporate action for fundraising. While it indicates capital raising activity, it is subject to approvals and doesn't immediately translate to a significant positive or negative impact without further details on the use of funds or market reaction.
Mukka Proteins Limited has submitted applications to BSE Limited and National Stock Exchange of India Limited seeking in-principle approval for a preferential issue of 2,00,00,000 (Two Crore) Convertible Warrants. The issue price is ₹23.50 per warrant, aggregating to ₹47,00,00,000 (₹47 Crore). This preferential issue is subject to necessary approvals, including from the stock exchanges and shareholders.
The company has confirmed compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, including the maintenance of a Structured Digital Database for unpublished price sensitive information related to the preferential issue.
The Board of Directors of Mukka Proteins Limited, in a meeting held on June 12, 2026, resolved to create, issue, offer, and allot up to 2,00,00,000 Convertible Warrants at an issue price of ₹23.50 per warrant, aggregating up to ₹47 Crore. Warrant holders will have the right to apply for and be allotted one fully paid-up equity share of face value ₹1 each at a premium of ₹22.50 per share for each warrant within 18 months from the allotment date. The allotment is proposed to be made to specific individuals and entities belonging to the Non-Promoter Category. The relevant date for determining the floor price is June 12, 2026. The warrants and resulting equity shares will be subject to lock-in requirements as per SEBI ICDR Regulations.
A postal ballot notice has also been issued, with remote e-voting commencing on June 13, 2026, and closing on July 12, 2026. The results of the postal ballot will be announced within two working days of the closure of e-voting.
What to do with a filing like this
Mukka Proteins Limited filed this with the NSE as a statutory disclosure, categorised under equity fundraising. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mukka Proteins Limited. Read the original for the full detail.